Group 1 - The core point of the news is that Yuan Da Pharmaceutical (00512) has seen a stock increase of over 3% following the completion of patient enrollment for its global Phase III clinical trial of the innovative ophthalmic drug CBT-001 for treating pterygium [1] - The Phase III trial is a randomized, double-blind, placebo-controlled study aimed at enrolling 660 patients aged 12 and above, assessing the safety and efficacy of CBT-001 eye drops in reducing conjunctival congestion and preventing the progression of pterygium [1] - CBT-001 is developed by Cloudbreak Pharma Inc. and is an innovative modified product of the already marketed drug OFEV, which has shown high safety and clinical efficacy in previous trials [1] Group 2 - After China joined the international multi-center Phase III clinical trial for CBT-001, the first patient enrollment in China was achieved in March 2024 [2] - The company holds exclusive production and commercialization rights for CBT-001 in mainland China, Hong Kong, Macau, and Taiwan, covering indications for preventing pterygium growth and reducing conjunctival congestion [2]

Group 1 - KJ International (06822.HK) sold a total of 4,114,080 shares of China Construction Bank at an average price of approximately HKD 7.21 per share, totaling around HKD 29,663,000 excluding transaction costs [1] - High雅光学 (00907.HK) plans to establish different subsidiaries to engage in liquor, eyewear, and gold jewelry-related businesses [1] - Southern Manganese (01091.HK) aims to reduce group liabilities by HKD 300 million to HKD 500 million annually over the next five years [1] Group 2 - Stone Four Pharmaceutical Group (02005.HK) obtained the drug production registration certificate for calcium gluconate and sodium chloride injection (100ml) from the National Medical Products Administration [2] - Yanda Pharmaceutical (00512.HK) completed patient enrollment for the international multi-center Phase III clinical trial of the global innovative ophthalmic drug CBT-001 [2] - Zhaoke Ophthalmology-B (06622.HK) received FDA approval for the new drug trial application for cyclosporine eye gel [2] Group 3 - Anta Sports (02020.HK) granted a total of approximately 10.45 million reward shares [3] - Tencent Holdings (00700.HK) repurchased 980,000 shares at a cost of HKD 500 million on June 4 [3] - AIA Group (01299.HK) repurchased 3.25 million shares at a cost of HKD 215 million on June 4 [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 自願性公告 本集團全球創新眼科藥物 CBT-001 国际多中心 III 期臨床試驗完成全部患者入組 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，本集團用於治療翼狀胬肉的全球創新眼科藥物 CBT-001（GPN00153） 開展的國際多中心 III 期臨床試驗，近日完成了全球中心全部患者入組。該研究是一項 隨機、雙盲、安慰劑平行對照的 III 期臨床試驗，擬入組 660 例 12 周歲及以上的翼狀胬 肉伴結膜充血患者，旨在評估 CBT-001 滴眼液在減少結膜充血和預防翼狀胬肉進展方 面的安全性和有效性。此次，該產品臨床研究全部患者入組是本集團在五官科領域眼科 方向的又一次重 ...

Core Viewpoint - The announcement highlights the upcoming launch of the Iberis® RDN system, a renal denervation product developed by Shanghai Antong Medical Technology Co., Ltd., scheduled for presentation at the OCC2025 conference on May 31, 2025 [1][2] Group 1: Product Launch and Event Details - The Iberis® RDN system is set to be introduced at the 19th Oriental Cardiology Conference (OCC2025) [1] - The launch event will feature prominent medical professionals as chairs and speakers, including professors from Fudan University, Zhejiang University, and Basel University [1] - The event will be hosted by Professor Liu Jian from Peking University People's Hospital [1] Group 2: Product Features and Market Strategy - The Iberis® RDN system is the only globally approved renal denervation product compatible with both transradial access (TRA) and femoral access [2] - TRA enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [2] - The product will be jointly promoted in China by Antong Medical and Kainow Medical Technology (Wuhan) Co., Ltd., a subsidiary of United Pharmaceutical Group [2]

Core Insights - The article discusses significant licensing agreements in the biopharmaceutical industry, particularly focusing on the collaboration between Bristol-Myers Squibb (BMS) and BioNTech for the development of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, with a total potential payment of up to $11.1 billion [1][2][6]. Group 1: Licensing Agreements - BMS will pay BioNTech an upfront fee of $1.5 billion and up to $2 billion in annual payments before 2028, along with milestone payments that could total $7.6 billion [1][2]. - The agreement allows for shared global profits and losses between BMS and BioNTech, marking a shift from traditional licensing models [2][6]. Group 2: Market Dynamics - The PD-(L)1 market is projected to reach $52.5 billion by 2024, with a compound annual growth rate (CAGR) of 16% from 2021 to 2024, and the PD-1/VEGF bispecific antibodies are expected to become a cornerstone in a market potentially exceeding $100 billion by 2028 [3][4]. - The ADC (Antibody-Drug Conjugate) market is also growing rapidly, with a projected size of $14.5 billion by 2024 and a CAGR of 40% from 2021 to 2024 [4][5]. Group 3: Innovation and Collaboration - The article highlights a trend where multinational corporations are increasingly partnering with Chinese biotech firms to enhance their pipelines, driven by the need to overcome patent cliffs and the high cost of drug development in the U.S. [6][7]. - Chinese innovative drug companies are becoming more competitive, with significant increases in business development (BD) transactions, from $9.2 billion in 2020 to an expected $52.3 billion in 2024 [7][8]. Group 4: Clinical Development and Future Prospects - BioNTech's BNT327 has shown promising clinical trial results for treating locally advanced or metastatic triple-negative breast cancer, indicating its potential in a high-demand therapeutic area [2][5]. - The article emphasizes the importance of clinical trial execution quality and innovative drug characteristics in negotiating favorable terms in BD transactions [8][10].

Investment Rating - The investment rating for the pharmaceutical industry is "Recommended" (maintained) [1] Core Insights - Significant transactions are driving the revaluation of innovation value in the pharmaceutical sector, with notable deals such as a $60 billion transaction by 3SBio and a $50 billion forecasted deal by CSPC Pharmaceutical Group [3] - The 2025 ASCO conference highlighted ADC, bispecific antibodies, and tri-specific antibodies as key areas of focus, with promising clinical results reported by Chinese companies [4] - Chinese innovative pharmaceutical companies are leading breakthroughs in CAR-T technology, with significant advancements expected in 2025 [6] - The gout treatment market presents substantial potential, with a projected increase in patients in China from 170 million in 2020 to 240 million by 2030 [8] - The oral weight loss drug market is seeing increased activity from leading companies, with notable collaborations and clinical advancements [10] - The approval of the world's first flu RNA polymerase PB2 protein inhibitor offers new treatment options for flu resistance [12] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 2.21% over the past week, with a weekly increase of 3.30% [28] - Over the past month, the industry also outperformed the CSI 300 index by 4.57%, with a monthly increase of 6.42% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's current PE (TTM) is 34.03, slightly above the five-year historical average of 32.54 [45] 3. Recent Research Achievements - Recent reports highlight the steady growth of blood products and the acceleration of the import substitution process in inhalation preparations [48] 4. Recent Industry Policies and News - The State Council announced a reduction in tariffs on imports from the U.S., which may impact the pharmaceutical sector [51] - Several innovative drugs have received approval for clinical trials and market entry, indicating a robust pipeline for the industry [52][53] 5. Recommended Companies and Earnings Forecast - Companies recommended for investment include Changchun High & New Technology, Yifan Biotech, and Zhongsheng Pharmaceutical, among others, with a focus on areas such as gout treatment and CAR-T technology [14]

港股创新药包揽QDII涨幅榜 据Wind数据统计，截至6月2日，全市场310只QDII基金中，有256只产品年内净值增长，占比82.6%。其中有37只产品年内净值增长率超过30%，42只基金收益率超 过两成。 从历史来看，QDII基金业绩排名与投资主题高度相关，尤其是近几年，领跑的产品多为美股科技基金、黄金主题以及原油等大宗商品主题基金，但风水轮流转，年 内原油天然气、标普生物以及纳斯达克主题基金则多数告负。 相反，今年以来随着南下资金的涌入带动的估值抬升，投向港股的QDII产品表现更为亮眼，尤其是医药主题基金更是一骑绝尘，业绩排名前30的QDII几乎均重仓了 港股创新药板块。 以涨幅居首的汇添富香港优势精选为例，该基金年内已获得约71%的收益，从重仓股的风格来看，汇添富香港优势精选近三年来成为一只不折不扣的港股创新药主 题基金，在经历漫长的底部蛰伏后，该基金在年内终于"守得云开见月明"，包括荣昌生物、科伦博泰生物以及信达生物等重仓股的集体大涨，使得基金业绩遥遥领 先。 近期，创新药的行情被各种利好消息接连点火。 年内，"吃药"行情久别重逢，但与上一轮医药牛市不同，本轮涨幅亮眼的个股集中在创新药板块，且港股市 ...

Group 1 - The core viewpoint of the articles highlights the significant presence of Chinese innovative drugs on the international stage, with a record number of original research results presented at the 2025 ASCO annual meeting [1][2] - The Hong Kong stock market saw active trading in the pharmaceutical and biotechnology sector, with the Hong Kong Innovative Drug ETF (159567) experiencing a high opening but a subsequent decline of 0.77% [1] - Notable performance among component stocks included Junshi Biosciences rising over 2%, while major stocks like Innovent Biologics and WuXi Biologics faced declines [1] Group 2 - Citic Securities indicated that the concentration of innovative drug results signifies that Chinese pharmaceutical companies are rapidly advancing in international innovative research and development [2] - Some innovative drugs are targeting previously underserved indications, while others are challenging current standard treatment protocols (SOC) to reach broader markets [2] - The innovative drug industry is maintained at a rating of outperforming the broader market [2]

Core Viewpoint - The innovative pharmaceutical sector in China is transitioning from a "cold winter" to a "warm spring," indicating a new cycle of policy support and development, as evidenced by significant stock price increases in leading companies like Heng Rui Pharmaceutical [2][3]. Market Performance - The innovative drug sector has shown remarkable performance, with the Hang Seng Healthcare Index rising over 30% year-to-date as of May 26, 2023. Notable companies include Sanofi with a 210.86% increase and WuXi AppTec with a 94.17% increase [2]. - The unprofitable biotech index in Hong Kong has also risen over 39% year-to-date, with companies like Deciphera Pharmaceuticals-B seeing a staggering 456.92% increase [2]. Policy Support - The pharmaceutical industry is characterized by strong regulation and a "policy cyclicality." Since 2024, various supportive policies for innovative drugs have been implemented, including insurance funding and procurement adjustments [3]. - The sales of newly negotiated drugs from 2018 to 2024 exceeded 540 billion yuan, indicating significant room for growth in the utilization of medical insurance funds [3]. International Market Presence - Chinese innovative drug companies are increasingly gaining international market influence, with the number of new drugs entering clinical trials surpassing that of the U.S. from 2015 to 2024 [5]. - The number of international multi-center clinical trials in China has risen from 207 to 286 between 2020 and 2023, reflecting a strategic shift towards global markets [6]. Investment Challenges - Despite the growth, Chinese innovative drug companies face challenges in balancing investment and returns, with the average cost of developing a new drug reaching $1.778 billion [7]. - The market's perception of investment returns is cautious, as many companies struggle to achieve the necessary sales to recoup development costs [7]. Business Development (BD) Trends - The trend of business development (BD) has become a significant revenue source for leading innovative drug companies, with Heng Rui Pharmaceutical completing 14 licensing agreements totaling approximately $14 billion [10]. - The global pharmaceutical market has seen a surge in major transactions, with 42% of significant licensing deals in 2025 originating from China [9]. Valuation Shifts - The valuation of unprofitable biotech companies is shifting from a focus on technical pipelines to a comprehensive assessment of commercialization capabilities, indicating a maturation of the investment landscape [13]. - The market is beginning to adopt a "finality thinking" approach to pricing unprofitable drug companies, allowing for short-term losses if core products demonstrate global competitiveness [13]. Future Outlook - The Chinese innovative drug sector is at a critical juncture, with expectations of the first blockbuster drugs generating over $6 billion in annual sales within the next 3-5 years, supported by strong clinical research capabilities and a global commercial framework [16].

Core Insights - The innovative drug industry is experiencing a "triple resonance" of policy support, industry upgrades, and performance recovery, leading to a restructuring of capital market valuation logic [1] - The market performance of innovative drug stocks has been notably strong, with significant increases in share prices for leading companies [2] - The Chinese innovative drug sector is transitioning from a "cold winter" to a "warm spring," indicating a new cycle of policy support and development [2][3] Market Performance - As of May 26, 2023, the healthcare sector in the Hang Seng Index has seen a year-to-date increase of over 30%, with specific companies like 三生制药 (Sihuan Pharmaceutical) rising by 210.86% [2] - The unprofitable biotech index in the Hong Kong market has also increased by over 39% year-to-date, with companies like 德琪医药 (Dechra Pharmaceuticals) seeing a staggering rise of 456.92% [2] Policy Environment - The innovative drug industry is characterized by strong regulation and a "policy cyclicality," with new supportive policies gradually being implemented since 2024 [3] - The total sales of newly negotiated drugs from 2018 to 2024 exceeded 540 billion yuan, indicating significant room for growth in the use of medical insurance funds [3] International Market Dynamics - In the first quarter of 2023, 60 pharmaceutical companies in China reported revenues exceeding 1 billion yuan, with 2 companies surpassing 10 billion yuan [4] - Chinese original innovative drugs have outnumbered those from the U.S. from 2015 to 2024, with a global share of 24% for original FIC drugs [4] R&D Trends - Chinese innovative drug companies are shifting focus from PD-1 and ADC markets to new targets such as peptide-conjugated drugs and cell therapies [5] - The number of international multi-center clinical trials in China has increased significantly, reflecting a strategic shift towards globalization [6] Investment Landscape - The average cost of developing a new drug is approximately $1.778 billion, necessitating substantial annual sales to recoup costs [7] - The investment landscape is challenging, with a significant portion of the market share still dominated by foreign companies, highlighting the need for Chinese firms to adopt global strategies [7] Business Development (BD) Strategies - There has been a notable increase in high-value BD transactions, with 21 deals exceeding $1 billion in early 2025 [8] - Chinese pharmaceutical companies are becoming key players in global pharmaceutical innovation, with 42% of major licensing deals involving Chinese firms [8] Valuation Shifts - The valuation of unprofitable biotech companies is increasingly based on their core product pipelines and commercial capabilities rather than just technical assessments [11] - The market is beginning to adopt a "finality thinking" approach to pricing unprofitable drug companies, allowing for short-term losses if core products are globally competitive [11] Challenges Ahead - Despite a favorable policy environment, innovative drug companies must navigate high R&D risks and potential market fluctuations [12] - The increasing regulatory scrutiny on Chinese drugs entering international markets may slow down the pace of globalization for these companies [13]